A probabilistic model for risk assessment of residual host cell DNA in biological products.
Biological products such as viral vaccines manufactured in cells contain residual DNA derived from host cell substrates used in production. It is theoretically possible that the residual DNA could transmit activated oncogenes and/or latent infectious viral genomes to subjects receiving the product, and induce oncogenic or infective events. A probabilistic model to estimate the risks due to residual DNA is proposed. The model takes account of enzyme inactivation process. It allows for more accurate risk assessment when compared to methods currently in use. An application of the method to determine safety factor of a vaccine product is provided.
MedImmune, One MedImmune Way, Gaithersburg, MD 20878, United States. yangh@medimmune.com
Harry
H
Yang
Lanju
L
Zhang
Mark
M
Galinski
D001688:Biological Products / Q000737:chemistry*; D004247:DNA / Q000032:analysis*; D004340:Drug Contamination / Q000706:statistics & numerical data*; D006801:Humans; D015233:Models, Statistical; D018570:Risk Assessment / Q000379:methods*
D001688:Biological Products; D004247:DNA